Contact:Justin Renz(617) email@example.comGina Nugent(617) firstname.lastname@example.org
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G. Kauffman MD, PhD, Chief Executive Officer , will ring the Nasdaq Closing Bell at 4:00 p.m. ET on Friday, November 4, 2016 at the Nasdaq MarketSite in New York City to commemorate the eighth anniversary of the Company's founding. "We are honored to participate in the Nasdaq Closing Bell ceremony in celebration of Karyopharm's anniversary," said Dr. Kauffman. "Eight years ago, Sharon founded Karyopharm with the discovery of novel small molecules inhibiting the nuclear export protein XPO1 as a novel anti-cancer strategy. Since that time, the Karyopharm team has significantly advanced a pipeline of SINE compounds, including selinexor, our lead product candidate, which is being evaluated in multiple mid- and later-phase clinical indications in over 1,800 patients across several high unmet need cancer indications. Looking ahead, we are in preparations to expand our ongoing Phase 2b clinical trial in heavily pretreated, penta-refractory multiple myeloma, and to initiate a pivotal Phase 3 clinical trial evaluating selinexor in patients with early relapsed myeloma, with the goal of obtaining regulatory approval and providing a much-needed oral treatment option for patients suffering with this incurable disease." A live stream of the Nasdaq Closing Bell ceremony will be available at https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx. Photos of the ceremony will be available at http://business.nasdaq.com/discover/market-bell-ceremonies. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,800 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.